Bs-452757-3 Unravelling the Arrhythmogenic Mechanisms of Short Qt Syndrome Type 3 in an Animal Model of KIR2.1 Gain-of-Function Mutation

Manuel, Ana Isabel Moreno; Macías, Álvaro; Cruz, Francisco M.; Pérez, Patricia Sánchez; Gutiérrez, Lilian K.; Carrascoso, Isabel; Pedrosa, María Linarejos Vera; Jiménez, Francisco Bermúdez; Jalife, José

doi:10.1016/j.hrthm.2023.03.312

Heart Rhythm

2023

DOI: 10.1016/j.hrthm.2023.03.312

|View full text |Cite

Bs-452757-3 Unravelling the Arrhythmogenic Mechanisms of Short Qt Syndrome Type 3 in an Animal Model of KIR2.1 Gain-of-Function Mutation

Ana Isabel Moreno Manuel¹,

Álvaro Macías²,

Francisco M. Cruz³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Alleviating the Effects of Short QT Syndrome Type 3 by Allele-Specific Suppression of the KCNJ2 Mutant Allele

Wilders

2024

IJMS

View full text Add to dashboard Cite

Short QT syndrome type 3 (SQTS3 or SQT3), which is associated with life-threatening cardiac arrhythmias, is caused by heterozygous gain-of-function mutations in the KCNJ2 gene. This gene encodes the pore-forming α-subunit of the ion channel that carries the cardiac inward rectifier potassium current (IK1). These gain-of-function mutations either increase the amplitude of IK1 or attenuate its rectification. The aim of the present in silico study is to test to which extent allele-specific suppression of the KCNJ2 mutant allele can alleviate the effects of SQT3, as recently demonstrated in in vitro studies on specific heterozygous mutations associated with long QT syndrome type 1 and 2 and short QT syndrome type 1. To this end, simulations were carried out with the two most recent comprehensive models of a single human ventricular cardiomyocyte. These simulations showed that suppression of the mutant allele can, at least partially, counteract the effects of the mutation on IK1 and restore the action potential duration for each of the four SQT3 mutations that are known by now. We conclude that allele-specific suppression of the KCNJ2 mutant allele is a promising technique in the treatment of SQT3 that should be evaluated in in vitro and in vivo studies.

show abstract

Alleviating the Effects of Short QT Syndrome Type 3 by Allele-Specific Suppression of the KCNJ2 Mutant Allele

Wilders

2024

IJMS

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Bs-452757-3 Unravelling the Arrhythmogenic Mechanisms of Short Qt Syndrome Type 3 in an Animal Model of KIR2.1 Gain-of-Function Mutation

Cited by 1 publication

References 0 publications

Alleviating the Effects of Short QT Syndrome Type 3 by Allele-Specific Suppression of the KCNJ2 Mutant Allele

Alleviating the Effects of Short QT Syndrome Type 3 by Allele-Specific Suppression of the KCNJ2 Mutant Allele

Contact Info

Product

Resources

About